|
Arcus Biosciences, Inc. (RCUS) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Arcus Biosciences, Inc. (RCUS) Bundle
Gain insights into Arcus Biosciences, Inc. (RCUS) valuation analysis using our sophisticated DCF Calculator! Equipped with real (RCUS) data, this Excel template enables you to adjust forecasts and assumptions to accurately determine the intrinsic value of Arcus Biosciences, Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.5 | 382.9 | 112.0 | 117.0 | 258.0 | 344.2 | 459.3 | 612.9 | 817.8 | 1,091.1 |
| Revenue Growth, % | 0 | 393.93 | -70.75 | 4.46 | 120.51 | 33.43 | 33.43 | 33.43 | 33.43 | 33.43 |
| EBITDA | -118.5 | 62.0 | -250.0 | -283.0 | -269.0 | -264.3 | -352.6 | -470.5 | -627.7 | -837.6 |
| EBITDA, % | -152.83 | 16.18 | -223.21 | -241.88 | -104.26 | -76.76 | -76.76 | -76.76 | -76.76 | -76.76 |
| Depreciation | 4.4 | 7.1 | 14.0 | 8.0 | 10.0 | 21.2 | 28.2 | 37.7 | 50.2 | 67.0 |
| Depreciation, % | 5.66 | 1.84 | 12.5 | 6.84 | 3.88 | 6.14 | 6.14 | 6.14 | 6.14 | 6.14 |
| EBIT | -122.9 | 54.9 | -264.0 | -291.0 | -279.0 | -265.5 | -354.3 | -472.7 | -630.7 | -841.6 |
| EBIT, % | -158.49 | 14.34 | -235.71 | -248.72 | -108.14 | -77.13 | -77.13 | -77.13 | -77.13 | -77.13 |
| Total Cash | 735.1 | 681.3 | 1,138.0 | 759.0 | 978.0 | 344.2 | 459.3 | 612.9 | 817.8 | 1,091.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.7 | 745.0 | 43.0 | 42.0 | 25.0 | 128.2 | 171.0 | 228.2 | 304.5 | 406.3 |
| Account Receivables, % | 2.19 | 194.58 | 38.39 | 35.9 | 9.69 | 37.23 | 37.23 | 37.23 | 37.23 | 37.23 |
| Inventories | -7.2 | -762.4 | -172.0 | .0 | .0 | -144.1 | -192.2 | -256.5 | -342.2 | -456.6 |
| Inventories, % | -9.25 | -199.13 | -153.57 | 0 | 0 | -41.85 | -41.85 | -41.85 | -41.85 | -41.85 |
| Accounts Payable | 15.7 | 10.3 | 20.0 | 17.0 | 18.0 | 42.9 | 57.2 | 76.3 | 101.8 | 135.9 |
| Accounts Payable, % | 20.23 | 2.68 | 17.86 | 14.53 | 6.98 | 12.45 | 12.45 | 12.45 | 12.45 | 12.45 |
| Capital Expenditure | -3.1 | -26.1 | -12.0 | -24.0 | -6.0 | -30.5 | -40.7 | -54.3 | -72.5 | -96.7 |
| Capital Expenditure, % | -3.94 | -6.81 | -10.71 | -20.51 | -2.33 | -8.86 | -8.86 | -8.86 | -8.86 | -8.86 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -116.7 | 53.3 | -265.0 | -296.8 | -279.0 | -261.3 | -348.6 | -465.1 | -620.6 | -828.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -94.2 | 40.8 | -141.7 | -486.8 | -257.0 | -204.8 | -341.4 | -455.6 | -607.8 | -811.0 |
| WACC, % | 11.21 | 11.22 | 11.24 | 11.24 | 11.24 | 11.23 | 11.23 | 11.23 | 11.23 | 11.23 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,664.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -827 | |||||||||
| Terminal Value | -8,962 | |||||||||
| Present Terminal Value | -5,264 | |||||||||
| Enterprise Value | -6,928 | |||||||||
| Net Debt | -102 | |||||||||
| Equity Value | -6,826 | |||||||||
| Diluted Shares Outstanding, MM | 90 | |||||||||
| Equity Value Per Share | -75.76 |
What You Will Get
- Real RCUS Financial Data: Pre-filled with Arcus Biosciences’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Arcus Biosciences’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- 🔍 Real-Life RCUS Financials: Pre-filled historical and projected data for Arcus Biosciences, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Arcus's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Arcus's valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Arcus Biosciences data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Arcus Biosciences' intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose the Arcus Biosciences Calculator?
- Accuracy: Reliable financial data from Arcus Biosciences ensures precise calculations.
- Flexibility: Tailored for users to explore and adjust inputs with ease.
- Time-Saving: Eliminate the complexities of creating a financial model from the ground up.
- Professional-Grade: Crafted with the expertise and standards expected at the CFO level.
- User-Friendly: Intuitive interface suitable for users of all financial backgrounds.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply them using real-world data.
- Researchers: Integrate advanced models into your studies or clinical trials.
- Investors: Evaluate your investment strategies and analyze the valuation of Arcus Biosciences, Inc. (RCUS).
- Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Pharmaceutical Entrepreneurs: Understand how large biotech companies like Arcus are assessed and valued.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Arcus Biosciences historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models illustrating intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Arcus Biosciences, Inc. (RCUS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for easy analysis of results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.